Date: Thu 01/11/2018 - Sat 31/10/2020
Provider: Luxottica Institute of Learning
Optometrist Credits: 2 Clinical Diagnostic Credits
Event Type(s): Online
Number: 09 929 3274
Dry Eye Disease is increasing in awareness in both patients and healthcare professionals. Increased awareness combined with an increasing prevalence is forcing eyecare professionals to take a more proactive approach to the investigation and treatment of dry eye disease. Colette Parkinson, consultant to the Dry Eye Institute in Sydney, has written this article to provide you with a systematic approach to the diagnosis and management of dry eye disease with a focus on meibomian gland dysfunction. Understand which tests to conduct and how to use specific test results to build a specific treatment plan for your patients. Learn how to look for non-obvious meibomian gland dysfunction and how to use the full scope of lisamine green staining for a comprehensive dry eye investigation. Understand the importance of conducting a blink assessment and screening for poor lid seal. Review the role that inflammation plays in the vicious cycle of dry eye disease and how to incorporate inflammation management into your dry eye treatment plans. Review both high and low technology diagnosis and treatment options, including blinking exercises, omega3 supplements, BlephEX, IPL and LipiFLow, and understand how to combine treatments for optimal patient outcomes. Read the article and take the online MCQ test to build your confidence in developing protocols for dry eye management suitable for your clinic.
- Understand what tests should be used to screen for and investigate dry eye disease and how to interpret the results
- Review the various uses for lisamine green in the diagnosis of dry eye disease
- Understand the role that inflammation plays in dry eye disease and how to manage this
- Review the pathophysiology of dry eye disease
- Review the mechanism of action of the various dry eye treatment options
- Review the anatomy of the meibomian glands and how this relates to meibomian gland dysfunction.